Survival of patients with newly diagnosed glioblastoma multiforme treated with RSR13 and radiotherapy: Results of a phase II new approaches to brain tumor therapy CNS consortium safety and efficacy study

Journal of Clinical Oncology

Volumn 20, Issue 14, 2002, Pages 3149-3155

  Kleinberg, Lawrence ^a   Grossman, S A ^a   Carson, K ^a   Lesser, G ^a   O'Neill, A ^a   Pearlman, J ^a   Phillips, P ^a   Herman, T ^a   Gerber, M ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EFAPROXIRAL;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLIOBLASTOMA; HUMAN; MALE; OXYGEN AFFINITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

ADULT; AGED; ANILINE COMPOUNDS; CHEMOTHERAPY, ADJUVANT; CONFIDENCE INTERVALS; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; PROPIONIC ACIDS; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY, ADJUVANT; SUPRATENTORIAL NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UNITED STATES;

EID: 0037099687     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.01.096     Document Type: Article

References (46)

1. RSR13: Effects on tumor oxygenation and response to therapy
2. RSR13, an allosteric effector of haemoglobin, and carbogen radiosensitize FSaII and SCCVII tumors in C3H mice
3. Allosteric effectors of hemoglobin as modulators of chemotherapy and radiation therapy in vitro and in vivo
4. Increased radiation response of FSaII fibrosarcomas in C3H mice following administration of an allosteric effector of hemoglobin-oxygen affinity
5. Direct measurement of PO2 distribution and bioreductive enzymes in human malignant brain tumors
6. In vivo radiation sensitivity of glioblastoma multiforme
7. Presidential address: Malignant glioma-a nemesis which requires clinical and basic investigation in radiation oncology
8. Increased efficacy of chemo- and radiotherapy by a hemoglobin solution in the 9L gliosarcoma
9. The New Approaches to Brain Tumor Therapy (NABTT) CNS Consortium: Organization, objectives and progress
10. The NABTT glioblastoma database: An objective means to select novel agents for phase III testing
11. Phase I trial to determine the safety, pharmacodynamics, and pharmacokinetics of RSR13, a novel radioenhancer, in newly diagnosed glioblastoma multiforme
12. Allosteric modifiers of hemoglobin: 1. Design, synthesis, testing and structure-allosteric activity relationships of novel hemoglobin oxygen affinity decreasing agents
13. Allosteric modifiers of hemoglobin: 2-[4-[[(3,5-Disubstituted anilino)carbonyl]methyl]phenoxy]-2-methylproprionic acid derivatives that lower the oxygen affinity of hemoglobin in red cell suspensions, in whole blood, and in vivo in rats
14. Enhanced oxygenation in vivo by allosteric inhibitors of hemoglobin saturation
15. The oxygen effect and reoxygenation
16. Restoration of tumor oxygenation after cytotoxic therapy by a perflubron emulsion/carbogen breathing
17. Selection of human cervical epithelial cells that posses reduced apoptotic potential to low-oxygen conditions
18. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors
19. Hypoxic stress proteins: Survival of the fittest
20. Cell cycle progression in human cells following re-oxygenation after extreme hypoxia: Consequences concerning initiation of DNA synthesis
21. Hypoxia arrests ovarian carcinoma cell cycle progression, but invasion is unaffected
22. Radiation, hypoxia and genetic stimulation: Implications for future therapies
23. Hypoxia-induced changes in radiation sensitivity in human melanoma cells: Importance of oxygen-regulated proteins, adenylate energy charge and cell cycle distribution
24. Tumor hypoxia and heterogeneity: Challenges and opportunities for the future
25. A posteffect of oxygen in irradiated bacteria: A submillisecond fast mixing study
26. The sensitivity of microorganisms to irradiation under controlled gas conditions
27. The time interval after pulsed irradiation within which injury to bacteria can be modified by dissolved oxygen
28. The radiation response of cells recovering after chronic hypoxia
29. Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers
30. Influence of oxygen tension on x-ray-induced chromosomal damage in ehrlich ascites tumor cells irradiated in vitro and in vivo
31. Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy
32. Oxygenation of human tumors: Evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements
33. Hypoxia and radiation response in human tumors
34. Tumor hypoxia adversely affects that prognosis of carcinoma of the head and neck
35. Oxygenation of carcinomas of the uterine cervix: Evaluation by computerized 02 tension measurements
36. Tumor oxygenation: A new predictive parameter in locally advanced cancer of the uterine cervix
37. Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy
38. Influence of the hypoxic subvolume on the survival of patients with head and neck cancer
39. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck
40. Oxygenation predicts radiation response and survival in patients with cervical cancer
41. Improved intratumoral oxygenation following RSR13 infusion in man: A case report
42. Phase II radiation therapy oncology group trial of weekly paclitaxel and conventional external beam radiation therapy for supratentorial glioblastoma multiforme
43. Phase II, two-arm RTOG trial (94-11) of bischloroethyl-nitrosourea plus accelerated hyperfractionated radiotherapy (64.0 or 70.4 Gy) based on tumor volume (>20 or < or = 20 cm (2), respectively) in the treatment of newly-diagnosed radiosurgery-ineligible glioblastoma multiforme patients
44. Single-arm, open-label phase II study of intravenously administered tirapazamine and radiation therapy for glioblastoma multiforme
45. Phase III study comparing three cycles of infusional BCNU/cisplatin followed by radiation and concurrent BCNU for patients with newly diagnosed supratentorial glioblastoma multiforme (ECOG 2934-SWOG 9508)